| |
|
|
Session 35a
Oral Abstract Presentations Clinical Trials and Cohorts Friday 8:30 - 10:30 am Auditorium |
| <%SessionModeratorsLabel%> | <%M1Name%> <%M1Aff%> <%ModAnd%> <%M2Name%> <%M2Aff%> |
| 08:30 176 | Results of the 2NN Study: A Randomized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together with Stavudine and Lamivudine F. van Leth1, E. Hassink1, P. Phanuphak2, S. Miller3, B. Gazzard4, P. Cahn5, R. Wood6,7, K. Squires8, C. Katlama9, B. Santos10, P. Robinson11, R. van Leeuwen1, F. Wit1, J.Lange*1,12, for the 2NN study group 1Intl Therapy Evaluation Ctr, Amsterdam, The Netherlands; 2HIV Netherlands Australia Thailand Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 3Innovir Inst, Johannesburg, South Africa; 4Chelsea and Westminster Hosp, London, UK; 5Fndn Huesped, Buenos Aires, Argentina; 6Somerset Hosp, Cape Town, South Africa; 7Univ of Cape Town, South Africa; 8Keck Sch of Med, Univ of Southern Califorinia, Los Angeles, CA; 9Hosp Pitie-Salpetriere, Paris, France; 10Hosp Nossa Senhora da Conceicao, Porto Alegre, Brazil; 11Boehringer Ingelheim, Ridgefield, CT; and 12Academic Med Ctr, Amsterdam, The Netherlands |
| 08:45 177 | The NEAT Study: GW433908 Efficacy and Safety in ART-naïve Subjects, Final 48-week Analysis J Nadler*1, A Rodriguez-French2, J Millard3, P Wannamaker3 1Univ of South Florida Coll of Med, Tampa, FL; 2San Fernando Hosp, Panama City, Panama; and 3GlaxoSmithKline, Research Triangle Park, NC |
| 09:00 178 | The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced Subjects with Virological Failure (24 Week Results) E DeJesus*1, A LaMarca2, M Sension3, C Beltran4, P Yeni5 1Infectious Disease Clin, Altamonte Springs, FL; 2TheraFirst Med, Ft Lauderdale, FL; 3N Broward Hosp Dist, Ft Lauderdale, FL; 4Hosp Trudeau, Santiago, Chile; and 5Hosp Bichat, Paris, France |
| 09:15 179 | Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor Experienced Patients: BI 1182.52 J Gathe*1, Veronika M. Kohlbrenner 2, Gerald Pierone3, Keikawus Arasteh4, Rafael Rubio5, R. LaLonde 6, Peter Piliero7, Scott McCallister2, Sandra Garfinkel2, Ricardo Chaves2, Geoffrey M. Mukwaya2, Catherine Dohnanyi2, S Shaw2, U Drees2, D Mayers2 1Houston, TX; 2Boehringer Ingelheim, Ridgefield, CT; 3Treasure Coast Infectious Disease Consultants, Vero Beach, FL; 4Epimed GmbH, Berlin, Germany; 5Hosp 12 de Oct Pabellon de Med Communitaria Unidad de VIH, Madrid, Spain; 6Montreal Chest Inst, Canada; and 7Albany Med Coll, NY |
| 09:30 180 | Changes in AIDS, Death Rates, and Survival after AIDS in the EuroSIDA Study: 1994 A. Mocroft*1, B. Ledergerber2, C. Katlama3, O. Kirk4, P. Reiss5, A. d'Arminio Monforte6, B. Knysz7, M. Dietrich8, A. N. Phillips1, J. D. Lundgren4, the EuroSIDA study group 1Royal Free and Univ Coll Med Sch, London, UK; 2Univ Hosp, Zurich, Switzerland; 3Hosp de la Pitie-Saltpetiere, Paris, France; 4Hvidovre Hosp, Denmark; 5Academic Med Ctr, Amsterdam, The Netherlands; 6Hosp L Sacco, Milan, Italy; 7Wroclaw Univ, Poland; and 8Bernhard-Nocht-Inst for Tropical Med, Hamburg, Germany |
| 09:45 181 | Does It Matter Where You Came From? Prognosis of Patients Starting Potent Therapy, According to Initial Response J. A. C. Sterne*1, M. May1, D. Costagliola2, P. Pezzotti3, B. Ledergerber4, F. de Wolf5, J. Lundgren6, J. S. Fusco7, S. Staszewski8, F. Raffi9, R. S. Hogg10, A. N. Phillips11, M. J. Gill12, G. Fatkenheuer13, G. Chêne14 1Univ of Bristol, UK; 2Ctr Hosp Univ Pitie-Salpetriere, Paris, France; 3Inst Superiore di Sanita, Rome, Italy; 4Univ of Zurich, Switzerland; 5HIV Monitoring Fndn, Amsterdam, The Netherlands; 6Hvidovre Univ Hosp, Denmark; 7GlaxoSmithKline, Research Triangle Park, NC; 8J W Goethe Univ, Frankfurt, Germany; 9Univ Hosp, Hotel-Dieu, Nantes, France; 10British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada; 11Royal Free and Univ Coll Med Sch, London, UK; 12Univ of Calgary, Canada; 13Klinikum Univ Regensburg, Germany; and 14Univ Victor Segalen, Bordeaux, France |
| 10:00 182 | The Impact of Baseline Plasma HIV RNA and Adherence on Response to Therapy and Mortality After the Initiation of HAART E Wood*, R S Hogg, B Yip, R Quercia, P R Harrigan, M V O'Shaughnessy, J S Montaner British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada |
| 10:15 183 | How Hard Is HAART? Residual Viral Replication and Evolution in Lymphoid Tissue during Sustained Control of Viremia Jan van Lunzen*1, B Zöllner1, HJ Stellbrink1, C Schneider1, O Degen1, S Staszewski2, S Christensen3, L Ruiz4, B Clotet4, K Tenner-Racz5, P Racz5 1Univ Hosp Eppendorf, Hamburg, Germany; 2Univ of Frankfurt, Germany; 3Münster, Germany; 4Fundacio IrsiCaixa, Barcelona, Spain; and 5Bernhard-Nocht-Inst, Hamburg, Germany |